The Foundation Fighting Blindness has allowed public open access to de-identified 4-year data from individuals participating ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.

Michaelides is professor at UCL Institute of Ophthalmology and Moorfields Eye Hospital, London.

The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, ...

The timeline for the proposed Alcon acquisition of STAAR Surgical has once again been extended as STAAR announced amendments ...

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes ...

SriniVas R. Sadda, MD, FARVO, a professor of ophthalmology at UCLA and the Doheny Eye Institute, discussed advancements in ophthalmological imaging technology, specifically focusing on the Silverstone ...

The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related ...

Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of ...

A study reveals that cryopreserved amniotic membrane enhances recovery and reduces infection risk in post-corneal ...